Blue­print scores first FDA OK for a pre­ci­sion GIST can­cer drug, just ahead of a ri­val treat­ment. And the price is a big sur­prise

Hit­ting the reg­u­la­to­ry fin­ish line just ahead of a pos­si­ble pre­ci­sion ri­val, Blue­print Med­i­cines has scored its first FDA OK. The green light came through for avapri­tinib, to be dubbed Ay­vak­it on the mar­ket.

Blue­print’s $BPMC crew, head­ed by CEO Jeff Al­bers, got an ac­cel­er­at­ed OK ahead of the pri­or­i­ty re­view PDU­FA date of Feb­ru­ary 14, in keep­ing with a slew of can­cer drugs that have war­rant­ed spot­light treat­ment at the agency. It’s pre­cise­ly tar­get­ed against a niche: gas­troin­testi­nal stro­mal tu­mor — GIST — with a platelet-de­rived growth fac­tor re­cep­tor al­pha (PDGFRA) ex­on 18 mu­ta­tion, in­clud­ing PDGFRA D842V mu­ta­tions.

That pa­tient group scored an over­all re­sponse rate of 84%.

But there are some flies in the oint­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER